Whole genomes redefine the mutational landscape of pancreatic cancer
Pancreatic cancer remains one of the most lethal of malignancies and a major health
burden. We performed whole-genome sequencing and copy number variation (CNV) …
burden. We performed whole-genome sequencing and copy number variation (CNV) …
[HTML][HTML] Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells
N Eling, L Reuter, J Hazin, A Hamacher-Brady… - …, 2015 - ncbi.nlm.nih.gov
Oncogenic KRas reprograms pancreatic ductal adenocarcinoma (PDAC) cells to states
which are highly resistant to apoptosis. Thus, a major preclinical goal is to identify effective …
which are highly resistant to apoptosis. Thus, a major preclinical goal is to identify effective …
Molecular characteristics of pancreatic ductal adenocarcinoma
NA Ottenhof, RF de Wilde, A Maitra… - Pathology research …, 2011 - Wiley Online Library
Pancreatic cancer is an almost universally lethal disease and despite extensive research
over the last decades, this has not changed significantly. Nevertheless, much progress has …
over the last decades, this has not changed significantly. Nevertheless, much progress has …
Pancreatic cancer genomics
Pancreatic cancer is one of the most lethal malignancies. The overall median survival even
with treatment is only 6–9 months, with almost 90% succumbing to the disease within a year …
with treatment is only 6–9 months, with almost 90% succumbing to the disease within a year …
Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival
RA Burkhart, Y Peng, ZA Norris, RM Tholey… - Molecular Cancer …, 2013 - AACR
Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death
in the United States, with a 95% five-year mortality rate. For over a decade, gemcitabine …
in the United States, with a 95% five-year mortality rate. For over a decade, gemcitabine …
Very long-term survival following resection for pancreatic cancer is not explained by commonly mutated genes: results of whole-exome sequencing analysis
M Dal Molin, M Zhang, RF De Wilde, NA Ottenhof… - Clinical Cancer …, 2015 - AACR
Purpose: The median survival following surgical resection of pancreatic ductal
adenocarcinoma (PDAC) is currently< 20 months. However, survival≥ 10 years is achieved …
adenocarcinoma (PDAC) is currently< 20 months. However, survival≥ 10 years is achieved …
[HTML][HTML] Clinical and molecular characterization of HER2amplified-pancreatic cancer
Background Pancreatic cancer is one of the most lethal and molecularly diverse
malignancies. Repurposing of therapeutics that target specific molecular mechanisms in …
malignancies. Repurposing of therapeutics that target specific molecular mechanisms in …
HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients
NG Richards, DW Rittenhouse, B Freydin… - Annals of …, 2010 - journals.lww.com
Background: Pancreatic ductal adenocarcinoma (PDA) is a devastating disease that killed
nearly 38,000 people in the United States this past year. Objective: Treatment of PDA …
nearly 38,000 people in the United States this past year. Objective: Treatment of PDA …
Somatic variation and cancer: therapies lost in the mix
AV Biankin, TJ Hudson - Human genetics, 2011 - Springer
Cancer arises as a consequence of mutations in genomes of cancer cells, which over time
allow them to proliferate and spread to distant sites. Large-scale sequencing of cancer …
allow them to proliferate and spread to distant sites. Large-scale sequencing of cancer …
A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma
D Subasinghe, N Acott, MP Kumarasinghe - Gastrointestinal Endoscopy, 2019 - Elsevier
Human epidermal growth factor receptor 2 (HER2) status determines gastric/
gastroesophageal junction (GEJ) adenocarcinomas that benefit from targeted therapy; …
gastroesophageal junction (GEJ) adenocarcinomas that benefit from targeted therapy; …